D. Western Therapeutics Institute, Inc.

Tokyo Stock Exchange 4576.T

D. Western Therapeutics Institute, Inc. Capital Expenditure for the year ending December 31, 2023: USD -105.87 K

D. Western Therapeutics Institute, Inc. Capital Expenditure is USD -105.87 K for the year ending December 31, 2023, a -41.49% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • D. Western Therapeutics Institute, Inc. Capital Expenditure for the year ending December 31, 2022 was USD -74.82 K, a -197.14% change year over year.
  • D. Western Therapeutics Institute, Inc. Capital Expenditure for the year ending December 31, 2021 was USD -25.18 K, a 49.24% change year over year.
  • D. Western Therapeutics Institute, Inc. Capital Expenditure for the year ending December 31, 2020 was USD -49.60 K, a 0.00% change year over year.
  • D. Western Therapeutics Institute, Inc. Capital Expenditure for the year ending December 31, 2019 was USD 0.00.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
SV Wall Street
Tokyo Stock Exchange: 4576.T

D. Western Therapeutics Institute, Inc.

CEO Mr. Yuichi Hidaka
IPO Date Oct. 23, 2009
Location Japan
Headquarters CK21 Hirokoujifushimi Bldg.
Employees 21
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension. The company was founded in 1999 and is headquartered in Nagoya, Japan.

StockViz Staff

February 8, 2025

Any question? Send us an email